Joshua Zeidner

36PUBLICATIONS

192CO-AUTHORS

Medical molecular engineering of nucleic acids and proteinsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (36)

Sort by Publication Date:

|Jul 03, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Jul 02, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 29, 2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Feb 03, 2026

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Joshua F Zeidner, Jayanshu Jain, Rina Li Welkie

|Nov 25, 2025

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Wei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek

|Jun 25, 2025

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.

Eric D Eisenmann, Ronan Swords, Ying Huang

Pageof 6

Frequent Collaborators

Yazan Madanat

Brian J Druker

Tara L Lin

Naval G Daver

Elie Traer

Alice S Mims

Rami S Komrokji

Yasmin Abaza

Daniel A Pollyea

Nathan D Montgomery

Frequent Collaborators

Yazan Madanat

Brian J Druker

Tara L Lin

Naval G Daver